The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A

BMC Medicine

Volumn 8, Issue , 2010, Pages

  Dedieu, S ^a,b   Canron, X ^a,b   Rezvani, H R ^a,b   Bouchecareilh, M ^a,b   Mazurier, F ^a,b   Sinisi, R ^c   Zanda, M ^c   Moenner, M ^a,b   Bikfalvi, A ^a,b   North, S ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; ACTIVATING TRANSCRIPTION FACTOR 4; AMIFOSTINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LENTIVIRUS VECTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN ELF 2ALPHA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS MODULATOR; SCAVENGER; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CELL PROTECTION; CELL STRAIN MCF 7; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IN VITRO STUDY; LIGAND BINDING; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SECRETION; RNA INTERFERENCE; UPREGULATION; BIOSYNTHESIS; CELL CULTURE; CELL LINE; DRUG EFFECT; GENE EXPRESSION; METABOLISM; TRANSCRIPTION INITIATION;

AMIFOSTINE; ANGIOGENESIS MODULATING AGENTS; CELL LINE; CELLS, CULTURED; FREE RADICAL SCAVENGERS; GENE EXPRESSION; HUMANS; TRANSCRIPTIONAL ACTIVATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77952283596     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-8-19     Document Type: Article

References (57)

1. News and products notes. Formulary 1996, 31:152.
2. Shaw LM, Bonner HS, Brown DQ. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse. Drug Metab Dispos 1994, 22:895-902.
3. Calabro-Jones PM, Fahey RC, Smoluk GD, Ward JF. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol Relat Stud Phys Chem Med 1985, 47:23-27. 10.1080/09553008514550041, 2982751.
4. Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs 2002, 13:181-209. 10.1097/00001813-200203000-00001, 11984063.
5. Smoluk GD, Fahey RC, Calabro-Jones PM, Aguilera JA, Ward JF. Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. Cancer Res 1988, 48:3641-3647.
6. Koukourakis MI. Amifostine: is there evidence of tumor protection?. Semin Oncol 2003, 30:18-30. 10.1053/j.seminoncol.2003.11.014, 14727237.
7. List AF, Gerner EW. Amifostine: a tonic or toxin to myeloid progenitors. Leuk Res 2000, 24:1009-1011. 10.1016/S0145-2126(00)00081-3, 11077114.
8. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 1980, 40:1519-1524.
9. Lee EJ, Gerhold M, Palmer MW, Christen RD. p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection. Br J Cancer 2003, 88:754-759. 10.1038/sj.bjc.6600779, 2376343, 12618886.
10. North S, El-Ghissassi F, Pluquet O, Verhaegh G, Hainaut P. The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene 2000, 19:1206-1214. 10.1038/sj.onc.1203413, 10713709.
11. Pluquet O, North S, Bhoumik A, Dimas K, Ronai Z, Hainaut P. The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase. J Biol Chem 2003, 278:11879-11887. 10.1074/jbc.M207396200, 12531896.
12. Pluquet O, North S, Richard MJ, Hainaut P. Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity. Biochem Pharmacol 2003, 65:1129-1137. 10.1016/S0006-2952(02)01655-6, 12663048.
13. Koukourakis MI, Giatromanolaki A, Chong W, Simopoulos C, Polychronidis A, Sivridis E, Harris AL. Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1 alpha. Cancer Chemother Pharmacol 2004, 53:8-14.
14. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732. 10.1038/nrc1187, 13130303.
15. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25. 10.1210/er.18.1.4, 9034784.
16. Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007, 62:179-213. 10.1016/j.critrevonc.2007.01.006, 17324579.
17. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006, 7:359-371. 10.1038/nrm1911, 16633338.
18. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007, 130:691-703. 10.1016/j.cell.2007.06.054, 17719546.
19. Kotch LE, Iyer NV, Laughner E, Semenza GL. Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol 1999, 209:254-267. 10.1006/dbio.1999.9253, 10328919.
20. Yun H, Lee M, Kim SS, Ha J. Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. J Biol Chem 2005, 280:9963-9972. 10.1074/jbc.M412994200, 15640157.
21. Drogat B, Auguste P, Nguyen DT, Bouchecareilh M, Pineau R, Nalbantoglu J, Kaufman RJ, Chevet E, Bikfalvi A, Moenner M. IRE1 signaling is essential for ischemia-induced vascular endothelial growth factor-A expression and contributes to angiogenesis and tumor growth in vivo. Cancer Res 2007, 67:6700-6707. 10.1158/0008-5472.CAN-06-3235, 17638880.
22. Drogat B, Bouchecareilh M, North S, Petibois C, Deleris G, Chevet E, Bikfalvi A, Moenner M. Acute L-glutamine deprivation compromises VEGF-a upregulation in A549/8 human carcinoma cells. J Cell Physiol 2007, 212:463-472. 10.1002/jcp.21044, 17348020.
23. Lemin AJ, Saleki K, van Lith M, Benham AM. Activation of the unfolded protein response and alternative splicing of ATF6alpha in HLA-B27 positive lymphocytes. FEBS Lett 2007, 581:1819-1824. 10.1016/j.febslet.2007.03.069, 17442311.
24. Roybal CN, Yang S, Sun CW, Hurtado D, Vander Jagt DL, Townes TM, Abcouwer SF. Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4. J Biol Chem 2004, 279:14844-14852. 10.1074/jbc.M312948200, 14747470.
25. Zhang C, Cai Y, Adachi MT, Oshiro S, Aso T, Kaufman RJ, Kitajima S. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem 2001, 276:35867-35874. 10.1074/jbc.M100747200, 11447214.
26. Colavitti R, Pani G, Bedogni B, Anzevino R, Borrello S, Waltenberger J, Galeotti T. Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J Biol Chem 2002, 277:3101-3108. 10.1074/jbc.M107711200, 11719508.
27. Abid MR, Spokes KC, Shih SC, Aird WC. NADPH oxidase activity selectively modulates vascular endothelial growth factor signaling pathways. J Biol Chem 2007, 282:35373-35385. 10.1074/jbc.M702175200, 17908694.
28. Gately S, Tsanaclis AM, Takano S, Klagsbrun M, Brem S. Cells transfected with the basic fibroblast growth factor gene fused to a signal sequence are invasive in vitro and in situ in the brain. Neurosurgery 1995, 36:780-788. 10.1097/00006123-199504000-00020, 7596510.
29. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 1997, 94:10868-10872. 10.1073/pnas.94.20.10868, 23512, 9380726.
30. Stathakis P, Lay AJ, Fitzgerald M, Schlieker C, Matthias LJ, Hogg PJ. Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin. J Biol Chem 1999, 274:8910-8916. 10.1074/jbc.274.13.8910, 10085135.
31. Xia C, Meng Q, Liu LZ, Rojanasakul Y, Wang XR, Jiang BH. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 2007, 67:10823-10830. 10.1158/0008-5472.CAN-07-0783, 18006827.
32. Giannopoulou E, Katsoris P, Kardamakis D, Papadimitriou E. Amifostine inhibits angiogenesis in vivo. J Pharmacol Exp Ther 2003, 304:729-737. 10.1124/jpet.102.042838, 12538828.
33. Plasswilm L, Hanjalic A, Hoeper J, Cordes N, Tannapfel A. Microvessel density and endothelial cell proliferation after amifostine (Ethyol) administration in vivo. Anticancer Res 1999, 19:4241-4245.
34. Giannopoulou E, Papadimitriou E. Amifostine has antiangiogenic properties in vitro by changing the redox status of human endothelial cells. Free Radic Res 2003, 37:1191-1199. 10.1080/10715760310001612559, 14703731.
35. Grdina DJ, Kataoka Y, Murley JS, Hunter N, Weichselbaum RR, Milas L. Inhibition of spontaneous metastases formation by amifostine. Int J Cancer 2002, 97:135-141. 10.1002/ijc.1592, 11774255.
36. Grdina DJ, Kataoka Y, Murley JS, Swedberg K, Lee JY, Hunter N, Weichselbaum RR, Milas L. Antimetastatic effectiveness of amifostine therapy following surgical removal of Sa-NH tumors in mice. Semin Oncol 2002, 29:22-28. 10.1053/sonc.2002.37357, 12577239.
37. Namba T, Hoshino T, Tanaka K, Tsutsumi S, Ishihara T, Mima S, Suzuki K, Ogawa S, Mizushima T. Up-regulation of 150-kDa oxygen-regulated protein by celecoxib in human gastric carcinoma cells. Mol Pharmacol 2007, 71:860-870. 10.1124/mol.106.027698, 17167033.
38. Meier T, Issels RD. Degradation of 2-(3-aminopropylamino)-ethanethiol (WR-1065) by Cu-dependent amine oxidases and influence on glutathione status of Chinese hamster ovary cells. Biochem Pharmacol 1995, 50:489-496. 10.1016/0006-2952(95)00164-U, 7646554.
39. Rezvani HR, Dedieu S, North S, Belloc F, Rossignol R, Letellier T, de Verneuil H, Taieb A, Mazurier F. Hypoxia-inducible factor-1alpha, a key factor in the keratinocyte response to UVB exposure. J Biol Chem 2007, 282:16413-16422. 10.1074/jbc.M611397200, 17400550.
40. Averous J, Maurin AC, Bruhat A, Jousse C, Arliguie C, Fafournoux P. Induction of IGFBP-1 expression by amino acid deprivation of HepG2 human hepatoma cells involves both a transcriptional activation and an mRNA stabilization due to its 3'UTR. FEBS Lett 2005, 579:2609-2614. 10.1016/j.febslet.2005.03.077, 15862298.
41. Sato Y, Rifkin DB. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol 1988, 107:1199-1205. 10.1083/jcb.107.3.1199, 2115297, 3417781.
42. Bachy CM, Fazenbaker CA, Kifle G, McCarthy MP, Cassatt DR. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys. Oncology 2004, 67:187-193. 10.1159/000081316, 15557777.
43. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks KL, Wood SM, Gatter KC, Harris AL, Pugh CW, Ratcliffe PJ, Maxwell PH. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 1998, 92:2260-2268.
44. Lee AH, Iwakoshi NN, Glimcher LH. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol 2003, 23:7448-7459. 10.1128/MCB.23.21.7448-7459.2003, 207643, 14559994.
45. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 2001, 107:881-891. 10.1016/S0092-8674(01)00611-0, 11779464.
46. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, Sadri N, Yun C, Popko B, Paules R, Stojdl DF, Bell JC, Hettmann T, Leiden JM, Ron D. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 2003, 11:619-633. 10.1016/S1097-2765(03)00105-9, 12667446.
47. Novoa I, Zeng H, Harding HP, Ron D. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. J Cell Biol 2001, 153:1011-1022. 10.1083/jcb.153.5.1011, 2174339, 11381086.
48. Pages G, Berra E, Milanini J, Levy AP, Pouyssegur J. Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Chem 2000, 275:26484-26491. 10.1074/jbc.M002104200, 10849421.
49. Yoshino Y, Aoyagi M, Tamaki M, Duan L, Morimoto T, Ohno K. Activation of p38 MAPK and/or JNK contributes to increased levels of VEGF secretion in human malignant glioma cells. Int J Oncol 2006, 29:981-987.
50. Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP, Ron D. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 2000, 287:664-666. 10.1126/science.287.5453.664, 10650002.
51. List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 1997, 90:3364-3369.
52. North S, Pluquet O, Maurici D, El-Ghissassi F, Hainaut P. Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol Carcinog 2002, 33:181-188. 10.1002/mc.10038, 11870884.
53. Murley JS, Kataoka Y, Hallahan DE, Roberts JC, Grdina DJ. Activation of NFkappaB and MnSOD gene expression by free radical scavengers in human microvascular endothelial cells. Free Radic Biol Med 2001, 30:1426-1439. 10.1016/S0891-5849(01)00554-8, 11390188.
54. Potgens AJ, Lubsen NH, van Altena MC, Vermeulen R, Bakker A, Schoenmakers JG, Ruiter DJ, de Waal RM. Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations. J Biol Chem 1994, 269:32879-32885.
55. Santos SC, Miguel C, Domingues I, Calado A, Zhu Z, Wu Y, Dias S. VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. Exp Cell Res 2007, 313:1561-1574. 10.1016/j.yexcr.2007.02.020, 17382929.
56. Adachi S, Natsume H, Yamauchi J, Matsushima-Nishiwaki R, Joe AK, Moriwaki H, Kozawa O. p38 MAP kinase controls EGF receptor downregulation via phosphorylation at Ser1046/1047. Cancer Lett 2009, 277:108-113. 10.1016/j.canlet.2008.11.034, 19138820.
57. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62. 10.1126/science.1104819, 15637262.